Clinical Trials
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
Latest Clinical Trial Results
CX717 Prevents Opioid-Induced Respiratory Depression While Maintaining Analgesia
IRVINE, Calif., Oct. 6, 2008--(BUSINESS WIRE)--Cortex Pharmaceuticals, Inc. (NYSE Alternext US (COR)) reported that top-line data from its second Phase IIa study in...
Presentation at the Obesity Society Annual Scientific Meeting Shows Weight Loss of 17 Pounds in 28 Weeks
MOUNTAIN VIEW, Calif., Oct. 6, 2008--(BUSINESS WIRE)--VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and...
TAK-390MR Data Presented at the American College of Gastroenterology Annual Meeting
ORLANDO, Fla., Oct. 6 /PRNewswire/ -- Combined results from two Phase 3 studies presented at the American College of Gastroenterology Annual Scientific Meeting (ACG)...
Results of 5,993 patient study UPLIFT(R) (Understanding Potential Long-term Impacts on Function with Tiotropium) presented today at European
BERLIN, Oct. 6 /PRNewswire/ -- Results of the UPLIFT(R) trial, presented today at the European Respiratory...
Results Presented at American College of Gastroenterology Annual Meeting Demonstrate Quality of Life Benefits and IBS Symptom Severity as Predictor of Clinical Response
ORLANDO, Fla., Oct. 6, 2008--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd....
PV-10 Treatment Was Well Tolerated by First 20 Patients
Response of Treated Lesions May Be a Good Predictor of Long-Term Outcome
KNOXVILLE, Tenn., Oct. 6, 2008--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a development-stage...
South San Francisco, Calif. and Melville, New York -- October 5, 2008 -- Genentech, Inc. (NYSE: DNA) and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today announced that a randomized Phase III study (BeTa Lung) evaluating Avastin® (bevacizumab) in...
www.bayerhealthcare.com.www.bayerscheringpharma.de.www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Bayer Schering Pharma is a worldwide...
Results Presented at American College of Gastroenterology Annual Meeting Demonstrate Quality of Life Benefits and IBS Symptom Severity as Predictor of Clinical Response
ORLANDO, FLA., October 6, 2008 – Salix Pharmaceuticals, Ltd....
More than 60 percent of moderate to severe patients achieved endoscopic response and more than 40 percent achieved endoscopic remission at Week 10 in data from a 54-week open-label study presented at the American College of Gastroenterology (ACG)...
PLYMOUTH MEETING, Pa., Oct. 6 /PRNewswire-FirstCall/ -- Genaera Corporation (NASDAQ:GENR) today reported data from its second Phase 1 clinical trial of trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and...
CX717 Prevents Opioid-Induced Respiratory Depression While Maintaining Analgesia
IRVINE, Calif.--(BUSINESS WIRE)--Cortex Pharmaceuticals, Inc. (NYSE Alternext US (COR)) reported that top-line data from its second Phase IIa study in opioid-induced...
PHILADELPHIA, Oct. 6 /PRNewswire-FirstCall/ -- Shire plc (NASDAQ:SHPGY) , the global specialty biopharmaceutical company, announced the results from a multidisciplinary analysis of in vitro and in vivo data of LIALDA(R) (mesalamine) versus Asacol(R)...
- Conference Call Scheduled for 9:00 AM ET Today -
SEATTLE, Oct. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) announced today that it has completed the planned interim analysis of the Phase 3, randomized, double-blind,...
-- Conference Call Scheduled for 9:00 AM ET Today --
SEATTLE, October 6, 2008 - Dendreon Corporation (Nasdaq: DNDN) announced today that it has completed the planned interim analysis of the Phase 3, randomized, double-blind, placebo-controlled...
- Improved Pharmacokinetic Characteristics of Naltrexone SR Associated with Better Tolerability in Clinical Trials -
PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (NASDAQ:OREX) , a biopharmaceutical company focused on the...
BERKELEY HEIGHTS, NJ – October 6, 2008 – Genta Incorporated (OTCBB: GNTA) announced the presentation of a progress update from the Company’s ongoing Phase 3 trial of Genasense® (oblimersen sodium) Injection, Genta’s lead oncology product,...
Results of 5,993 patient study UPLIFT(R) (Understanding Potential Long-term Impacts on Function with Tiotropium) presented today at European Respiratory Society Annual Congress, and published online in New England Journal of Medicine
BURLINGTON,...
Paul Kidwell
617.296.3854: Office
617.680.1088: Mobile
Investor Conference Call Scheduled for Today at 8:30 am EDT
CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX), today announced preliminary top-line results from...
Data from SONIC Trial Showed REMICADE Therapy is More Likely to Induce Steroid-Free Remission and Mucosal Healing Compared with Standard Immunomodulator, Azathioprine
ORLANDO, Fla., Oct. 6 /PRNewswire/ -- Data presented for the first time from the...
More...
